# US 2025/0082736 A1 · Particles and suspensions comprising hyaluronan degrading agents and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082736 A1
- Document ID: US20250082736A1
- Status: Published application
- Kind: A1
- Application number: 18/827,595
- Filed: 2024-09-06
- Published: 2025-03-13
- Earliest claimed: 2023-09-08
- Assignees: Elektrofi, Inc.
- Applicants: Elektrofi, Inc.
- Inventors: Paul Brown; Li-Chiun Cheng; Daniel Benjamin Dadon; Ashita Nair; Sakshi Singal; Chaitanya Sudrik; Winnie L. Zhang; Sadiqua Shadbar
- Web page: https://patentgrep.com/patent/US20250082736A1

## CPC

- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/385: {Serum albumin}
- C07K 16/2887: {against CD20}
- C07K 16/32: against translation products of oncogenes
- C12Y 302/01035: Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present disclosure provides, in various embodiments, stable injectable particle suspensions of therapeutic biologics and hyaluronan degrading agents that permit administration without the need for resuspension. In particular, the compositions disclosed herein are highly concentrated, low-volume injectable particle suspensions that increase bioavailability of therapeutic biologics.

## Claims

### Claim 1

A particle comprising at least one therapeutic biologic or a salt thereof, and a hyaluronan degrading agent.

### Claim 2 (depends on 1)

The particle of claim 1, wherein the hyaluronan degrading agent is hyaluronidase.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The particle of claim 1, wherein the hyaluronan degrading agent in the particle is less than about 1% by weight.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The particle of claim 1, wherein the particle has less than about 10% aggregation of the therapeutic biologic.

### Claim at position 10

-14. (canceled)

### Claim 15 (depends on 1)

The particle of claim 1, wherein the particle has a circularity of about 0.8 to about 1.00.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The particle of claim 1, wherein the particle has less than about 25% internal void spaces.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The particle of claim 1, wherein the particle has greater than about 60% therapeutic biologic by weight.

### Claim 20 (depends on 1)

The particle of claim 1, wherein the particle further comprises a carbohydrate, a pH adjusting agent, a salt, a chelator, a surfactant, a protein stabilizer, an emulsifier, an antiseptic, an amino acid, an antioxidant, a paraben, a bactericide, a fungicide, a preservative, or a combination thereof.

### Claim at position 17

-37. (canceled)

### Claim 38 (depends on 1)

The particle of claim 1, wherein the therapeutic biologic is an antibody or fragment thereof.

### Claim 39 (depends on 38)

The particle of claim 38, wherein the antibody is a human IgG or a monoclonal antibody.

### Claim at position 20

-42. (canceled)

### Claim 43 (depends on 1)

The particle of claim 1, wherein the therapeutic biologic is BSA.

### Claim at position 22

-54. (canceled)

### Claim 55

A pharmaceutically effective composition comprising:
a plurality of particles suspended in a pharmaceutically acceptable liquid carrier, wherein substantially all of the particles comprise at least one therapeutic biologic or a salt thereof, and a hyaluronan degrading agent.

### Claim 56 (depends on 55)

The composition of claim 55, wherein the concentration of the hyaluronan degrading agent in the composition is less than about 20000 U/mL.

### Claim 57 (depends on 55)

The composition of claim 55, wherein the hyaluronan degrading agent is hyaluronidase.

### Claim at position 26

-99. (canceled)

### Claim 100 (depends on 55)

The composition of claim 55, wherein the liquid carrier is non-aqueous.

### Claim 101 (depends on 100)

The composition of claim 100, wherein the non-aqueous liquid carrier is an organic solvent.

### Claim 102 (depends on 101)

The composition of claim 101, wherein the organic solvent comprises benzyl benzoate, coconut oil, cottonseed oil, fish oil, grape seed oil, hazelnut oil, hydrogenated vegetable oils, olive oil, palm seed oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, sunflower oil, walnut oil, corn oil, acetone, ethyl acetate, ethyl lactate, dimethylacetamide, dimethyl isosorbide, dimethyl sulfoxide, glycofurol, diglyme, methyl tert-butyl ether, N-methyl pyrrolidone, perfluorodecalin, polyethylene glycol, 2-pyrrolidone, tetrahydrofurfuryl alcohol, diglycerides, trigylcerides, medium-chain triglycerides (MCTs), caproic acid, caprylic acid, capric acid, lauric acid, ethyl laureate, triglycerides of the fractionated plant fatty acids C8 and C10, propylene glycol diesters of saturated plant fatty acids C8 and C10 (PGD), ethyl oleate, ethyl caprate, dibutyl adipate, fatty acid esters, hexanoic acid, octanoic acid, triacetin, diethyl glycol monoether, gamma-butyrolactone, eugenol, clove bud oil, citral, limonene, polyoxyl 40 hydrogenated castor oil, polyoxyl 35 castor oil, simple alcohols such as ethanol, octanol, hexanol, decanol, propanol, butanol, gamma-butyrolactone, tocopherol, octa-fluoropropane, (perfluorohexyl)octane, n-acetyltryptophan, ethyl laurate, methyl caprylate, ethyl caprylate, methyl caprate, methyl myristate, methyl oleate, methyl linoleate, dimethyl adipate, dibutyl suberate, diethyl sebacate, ethyl macadamiate, trimethylolpropane triisosterate, isopropyl laurate, isopropyl myristate, diethyl succinate, polysorbate esters, ethanol amine, propanoic acid, citral, anisole, anethol, benzaldehyde, linalool, caprolactone, phenol, thioglycerol, dimethylacetamide, diethylene glycol monoethyl ether, solketal, isosorbide dimethyl ether, ethyl formate, ethyl hexyl acetate, propylene glycol dicaprylate, caprylic triglyceride, ethyl linoleate, ethyl linolenate, or a combination thereof.

### Claim at position 30

-123. (canceled)

### Claim 124

A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising:
a plurality of particles suspended in a pharmaceutically acceptable liquid carrier, wherein substantially all of the particles comprise at least one therapeutic biologic or a salt thereof, and a hyaluronan degrading agent.

### Claim at position 32

-131. (canceled)

### Claim 132 (depends on 124)

The method of claim 124, wherein the disease or condition is cancer, inflammatory disease or an immune disease.

### Claim at position 34

-190. (canceled)

### Claim 191 (depends on 124)

The method of claim 124, wherein the composition is administered by a syringe or portable drug delivery injection device.

### Claim at position 36

-224. (canceled)
